Disclaimer:  The following information is drawn from materials prepared by candidates for promotion to full professor.  It is intended to illustrate activities and materials that might support promotion.  In using these materials, please note the following:

               *The Provost (and, in some cases, the President) are the University officers authorized to approve promotions.  All levels of review below these officers are advisory.

               *Only Departments are empowered to propose promotions, and the Divisional Dean is charged with transmitting such proposals to the Provost or returning them to the Department.

*The judgment of the Department, Dean, and Provost will therefore be critical to assessing qualification for promotion.

               *Materials considered by the Department, Dean, and Provost will also (and always) include confidential evaluations obtained from outside the University.  Materials considered by the Provost will include the confidential evaluations of the Dean and Department, and those considered by the Dean will include the confidential evaluations of the Department.

               *Thus, the following materials are ONLY PART of a complete proposal for promotion, whereas promotion is based on the ENTIRE proposal.   Therefore, it should not be assumed that a record comparable to that below will necessarily result in promotion, or that a record not comparable to that below will fail to result in promotion.  The Departmental Chair is likely to be the best source of advice as to whether promotion is feasible and, when it is not, what additional activity may result in qualification for promotion.

               *This document has been prepared as a tool for use by associate professors in the Division of the Biological Sciences.  Other individuals who may find it informative are Department Chairmen, Section Heads, Committee Chairmen, senior faculty and potential recruits.  Its intent is to help guide individuals and their departments as they think about promotion to Professor.  This document is not intended to list the elements that every promotion proposal will be expected to address.  The following information is presented for information purposes only and is not intended to create any contract or agreement, and its contents are subject to addition, deletion, and change without prior notice.

1.Name:

Gregory Karczmar

 

2.Department of PrimaryAppointment:

Radiology

 

Secondary appointments:

Medical Physics and Cancer Biology

 

3.Proposed rank:

PROFESSOR

 

4.Proposed track:

RESEARCH SCHOLAR (TENURE)

 

LAY SUMMARY:

Research: Dr. KarczmarÕs research focuses on improved methods for magnetic resonance imaging for the early detection and diagnosis of cancer as well as assessment of response to cancer therapies – both in animal studies and clinical studies. His research focuses on breast and prostate cancer, but also includes support for a variety of clinical trials of new cancer drugs.  The research is interdisciplinary and translational, and includes experiments on animal models, cells, and tissues, as will as clinical research with patients.  Working with  animal models of cancer, he demonstrated for the first time that non-invasive MRI measurements could predict the therapeutic effects of tumor oxygenating treatments.  This work has important clinical implications since it shows how MRI can be used to guide improved therapy for cancer patients.  He developed new methods for evaluating tumor blood flow by MRI.  These methods are referred to as Ôreference tissue methodsÕ and they allow more accurate measurement of the rate at which contrast agents are delivered to tumors.  He also introduced the use of high spectral and spatial resolution MR imaging – to improve both anatomic and functional imaging.  This new approach to imaging uses information about the structure of the magnetic resonance signal that is ignored in conventional imaging – and this significantly yields improvement in image quality.

Clinical:  Dr. Karczmar does not have a formal clinical role.  However, he does frequently work with clinicians to monitor the performance of the clinical magnetic resonance scanners and to optimize performance of the scanners. The candidate also provides advice on purchases of new equipment and on MR safety issues.

Administrative: Dr. Karczmar is the director of the Magnetic Resonance and Spectroscopy laboratory – which provides technical support for MRI studies of animal models of disease, cells, tissues, material, as well as clinical research involving patients.  Over 30 University of Chicago faculty members rely on services provided by the laboratory, and over 50 research associates, graduate students, technologists, faculty members, and post doctoral fellows do research in the laboratory either full time or part time.  There are about 10 core staff of the laboratory

Teaching:  Dr. Karczmar is a faculty member in the graduate medical physics program and teaches in some of the core courses of the program (in Medical Imaging and the associated laboratory practicum).  He also developed specialized MRI courses that are taught whenever there is sufficient demand.  He teaches  residents through giving noon conferences 10 – 15 times each year.   He mentors graduate students and post-doctoral  fellows in his laboratory as well as other graduate students and postdocs who use the laboratory occasionally.  Over the last 5 years, he has provided the bulk of instruction on MRI.

 

Other professional activities:

 

Reviewer for Magnetic Resonance in Medicine

Editorial Board – Magnetic Resonance in Medicine, 2001 - present

Reviewer for Magnetic Resonance Imaging

Reviewer for Neoplasia

Reviewer for International Journal of Radiation Oncology, Biology, and Biophysics

Reviewer for Journal of Magnetic Resonance Imaging

Reviewer for NMR in Biomedicine

Reviewer for Bioelectromagnetics

Reviewer for Kidney International

Reviewer for Academic Radiology

Reviewer for Magma

 

Reviewer,  Journal of the European Society for Therapeutic Radiology and Oncology, 2005

 

Research Advisory Committee, American Cancer Society of Illinois, 2001 - present

Imaging Committee, Cancer and Leukemia Group B,  2001 - present

 

Reviewer, Ad Hoc Study Section for Mellon Institute Research Resource Application, 2002.

Chair, NIH Special Emphasis Review Group; Imaging of Microcirculation in Diabetes, 2002

Reviewer of Imaging Protocols, Cancer and Leukemia Subgroup B, 2001 - present

Reviewer, NIH Shared Instrumentation 1992, 2001, 2002

Reviewer, NIH Diagnostic Radiology Study Section, 2001,2002, 2005

Reviewer, NIH, Radiation Study Section, 1998,1999,2003, 2004, 2005, nominated for position as permanent member for 2006.

Reviewer, Army Breast Cancer Research Program, Ad Hoc Study Section, 1997

Reviewer, NIH Review committee for Breast Cancer 'Insight Awards'

Reviewer, American Cancer Society of Illinois, 1999 - present

Reviewer, Ad Hoc NIH Study Section for Mellon Institute Research Resource, 2002

Reviewer, NIH Study Section on ÔBioengineering Research PartnershipsÕ, 2005

Reviewer, NIH Review Committee for ÔInnovation in Molecular Imaging ProbesÕ, 2005

Reviewer, California Breast Cancer Research Program, 2003, 2004, 2005

Reviewer, Israel Science Foundation, 2005

 

University Committees

Institutional Review Board 1991 –2003

Graduate Program in Medical Physics, Curriculum Committee, 1999.

Research Advisory Committee, Dept of Radiology, 1996- 1999.

Graduate Program in Medical Physics, Publicity Committee, present

Organizer of the contrast media research program, Dept of Radiology, 1998 - 2000

Organizer, Department of Radiology Research Seminars, 1999 - 2001.                 

Faculty Awards Committee, 2004 - 2005

 

COMMUNITY SERVICE

Mathletes Coach, Talala School, 2004,2005

Crete-Monee School District 201U Board of Education, 2005-present

 

Honors:

 

American Cancer Society Junior Faculty Research Award, 1993

Kurt Rossman Award for Excellence in Teaching, 1996

Senior Author on a paper that received the Radiological Society of North America Research

Prize in Physics, 1996.

Certificate of Appreciation, American Cancer Society, South Suburban Chicago Chapter, 1999.

Editorial Board, Magnetic Resonance in Medicine, 2001 – present

American Cancer Society Research Scholar, 2003

 

5.PRESENTATIONS

INVITED TALKS

 

1)     Investigation of metabolic disorders in patients and animal models using in vivo magnetic resonance spectroscopy.  International Symposium on Cell Function and Disease, Monterrey, Mexico, 1988.

 

2)     Use of radio frequency gradients for spatially resolved NMR and spectral editing.  XIII International Conference on Magnetic Resonance in Biological Systems, Madison, Wisconsin, 1988.

 

3)     MR studies of the metabolic response of tumors to therapy.  NIH Workshop on Applications of Magnetic Resonance to the Study and Treatment of Cancer, Bethesda, 1989.

 

4)     Applications of surface coils for in vivo magnetic resonance.  Society of Magnetic Resonance in Medicine, Educational Symposium, San Francisco, 1991.

 

5)     Physiological measurements with MRI.  Department of Pharmacology, Loyola University, 1993. 

 

6)     BOLD effect measurements in tumors.  MRI Research Center, Fox Chase Cancer Center, Philadelphia, PA., 1993.

 

7)     New approaches to measurement of tumor oxygenation.  University of Illinois at Chicago, Dept. of Radiology, 1994.

 

8)     Measurements of capillary permeability with MRI.  Northwestern University Dept. of Radiology, 1995.

 

9)     Use of magnetic resonance imaging to evaluate tumor oxygenation agents.  Cancer Study Group, International Society of Magnetic Resonance in Medicine, 1996

 

10) Comparison of magnetic resonance and oxygen electrode measurements.  Microscopy and Microanalysis Conference, St. Paul Minnesota, 1996.

 

11) MR measurements of effects of tumor oxygenating agents.  University of Minnesota, Magnetic Resonance Research Center, 1996.

 

12) Spectroscopic imaging of the water resonance with high spectral and spatial resolution, Carnegie Mellon University, 1997.

 

13) Functional imaging of tumors. University of California at San Francisco Department of Radiology, 1998.

 

14) MR studies of tumor oxygenation.  Stanford Department of Radiology, 1998.

 

15) Advantages of spectroscopic imaging tumors.  Cancer Study Group, International Society of Magnetic Resonance in Medicine, St. Louis, 1998

 

16) High spectral and spatial resolution magnetic resonance imaging.  University of Minnesota, Magnetic Resonance Research Center, 1998.

 

17) Differentiation of metastatic and non-metastatic tumors with contrast enhanced MRI.  Monsanto Corporate Research Center, St. Louis, Missouri, 1998.

 

18) Functional imaging of tumors. American Association of Physicists in Medicine, Nashville Tennessee, 1999.

 

19) New approaches to detection of MR contrast agents.  Nycomed Corporate Research, Wayne, PA., 1999.

 

20) MRI measurements correctly predict the relative effect of tumor oxygenating agents on hypoxic fraction.  International Society of Oxygen Transport to Tissue, Dartmouth College, 1999.

 

21) Functional and anatomic imaging of tumor vasculature:  High resolution MR spectroscopic imaging combined with a superparamagnetic contrast agent.  Contrast Media Research Meeting, Woodstock, Vermont, 1999.

 

22) High spectral and spatial resolution MRI with applications to contrast media dynamics. Dept. of Biology, Carnegie Mellon University, 1999.

 

23) Early detection of cancer.  American Cancer Society Illinois Division, Illinois, 1999.

 

24) MRI studies of tumor physiology.  Department of Radiation Oncology, Medical College of Wisconsin, 1999.

 

25) Detection of the BOLD effect in tumors.  St. Georges Medical Center, London, 1999.

 

26) Advantages of high spectral resolution for functional and anatomic MRI.  Department of Radiology, University of Pittsburgh, 2000.

 

27) Measurement of tumor capillary permeability using two MRI contrast agents of different molecular weights.  Guerbet Lecture Series, Paris, France, 2001

 

28) Increased sensitivity to contrast agents with high spectral and spatial resolution MRI.  Contrast Media Research Meeting, Woodstock, Vermont, 2001 

 

29) *DCEMRI for Early Evaluation of Response to Antiangiogenic Cancer TreatmentÓ, MRI Center, Clinical Center of Serbia, Belgrade, Yugoslavia, October 2001.  *Presenter – Dr. Milica Medved;  results of collaborative research.

 

30) High spectral and spatial resolution imaging for improved sensitivity to tumor microenvironments. Contrast Media Research Meeting, Capri, Italy, 2002.

 

31) Early detection of cancer.  American Cancer Society of Illinois, Oakbrook, Illinois, 2001.

 

32) Use of MRI to detect tumor response to therapy.  Cancer and Leukemia Group Meeting, Orlando, 2002.

 

33) High spectral and spatial resolution MRI of breast and other tissues.  Northwestern University Evanston Hospital Department of Radiology, 2003

 

34) High spectral and spatial resolution MRI of breast cancer; University of Washington at St Louis;  St. Louis MO., 2003

 

35) Anatomic and functional MRI of Cancer;  Physics Department Colloquium., University of Washington at St. Louis;  St. Louis MO. 2003.

 

36) *Clinical Breast MRI.  Kyoto College of Medical Tec,  Kyoto, Japan 2003 .  *Presenter - Dr. Gillian Newstead; results from collaborative research.

 

37)   *Breast MR for the Breast Cancer Patient,. McMaster University, Hamilton, Ontario, Canada, 2003. *Presenter - Dr. Gillian Newstead; results from collaborative research.   

 

38) New applications of MRI to cancer, American Cancer Society, Batavia Chapter, Geneva, Illinois, 2003.

 

39)  MRI measurements of tumor oxygenation.  Symposium on Advances in Imaging-Guided Diagnosis and Therapy, Round Top Texas, 2004

 

40)  New sources of contrast in MR images, Dartmouth College, 2004

 

41)  MRI approaches to Breast Cancer Screening and rapid evaluation of response to therapy;  Cancer Center Administrators Forum, 2004

 

42)  MRI imaging techniques for assessment of tumor response to therapy.  RSNA refresher course, Chicago, Illinois, 2004.

 

43) *MRI: Is it as good as all the hype? International Institute for Medical Education, Orlando, Florida, 2004.  *Presenter - Dr. Gillian Newstead; results from collaborative research.

 

44)  New functional and anatomic MR imaging approaches to detection and staging cancer; implications for targeted therapy.  Japan/US Cancer Therapy Symposium (JUCTS) on ÒNew Horizons of Targeted Treatment in Radiation OncologyÓ, Maui, Hawaii, 2005

 

45)   Vascular properties of tumors measured using intrinsic MRI contrast.  ISMRM Cancer Imaging Course, Miami, Florida, 2005.

 

 

*Talks with an asterisk indicate presentations by colleagues of the results of our collaborative research.